Invivyd (NASDAQ:IVVD) surged 25.22% on analyst upgrade and regulatory progress

Generated by AI AgentAinvest Pre-Market RadarReviewed byAInvest News Editorial Team
Tuesday, Dec 23, 2025 4:37 am ET1min read
IVVD
--
Aime RobotAime Summary

- Invivyd's stock jumped 25.22% pre-market after BTIG and H.C. Wainwright upgraded to Buy with $10 price targets, citing VYD2311's potential to outperform mRNA vaccines.

- FDA approved VYD2311's IND application for Phase 3 trials, while PEMGARDA showed 80% efficacy vs. 40-50% for mRNA vaccines in healthy individuals.

- The company secured $125M through a public offering led by

Cantor
Fitzgerald, with Phase 3 trial data expected by late 2026 to drive next-gen vaccine market positioning.

Invivyd (NASDAQ:IVVD) surged 25.2174% in pre-market trading on Dec. 23, 2025, following a strategic analyst upgrade and key regulatory progress.

BTIG analyst Thomas Shrader initiated coverage with a Buy rating and a $10 price target, highlighting the company’s antibody development expertise and the potential of its VYD2311 candidate to outperform mRNA vaccines. The firm cited VYD2311’s focus on stable viral epitopes and a pending Phase 3 trial readout by late 2026 as catalysts. H.C. Wainwright also raised its price target to $10, maintaining a Buy rating after the company unveiled its REVOLUTION clinical program.

Regulatory momentum fueled optimism, as the FDA approved Invivyd’s Investigational New Drug application for VYD2311, advancing trials DECLARATION and LIBERTY. The firm also secured $125 million through a public offering of 44 million shares, with Cantor Fitzgerald acting as lead manager. Additionally, Invivyd’s PEMGARDA, authorized in 2024, demonstrated 80% efficacy against current variants, contrasting with 40-50% effectiveness of mRNA vaccines in healthy individuals.

Analysts believe the recent developments position

Invivyd
to become a key player in the next-generation vaccine market. The company's Phase 3 trial timeline and positive early trial results could attract further investment and strategic partnerships in early 2026.

Investors are advised to monitor upcoming trial data and FDA feedback for potential volatility and investment opportunities.

Aime Insights

Aime Insights

ALERT: Biotech cash burn crisis! Which 3 stocks will survive the 2026 funding crunch? Screen for cash-rich innovators.

Is IVVD's 25% surge just the beginning? Discover which biotech stocks could double if FDA approvals accelerate in 2026.

Why did BTIG slap a $10 target on IVVD? Uncover the hidden upside in antibody stocks before trial results drop.

RSV vaccine war heats up: Should you buy IVVD's dip or bet on MENS' 50% rally? Compare next-gen biologics now.

Comments



Add a public comment...
No comments

No comments yet